Outcome of Board Meeting held on July 19, 2025.
ROSSARI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Rossari Biotech's Board of Directors, at its meeting on July 19, 2025, approved the unaudited financial results for the quarter ended June 30, 2025. On a consolidated basis, revenue from operations grew about 11% year-on-year to Rs. 5,437.16 million, while profit after tax slipped roughly 4% to Rs. 335.96 million. On a standalone basis, revenue rose about 22% year-on-year to Rs. 3,657.58 million and profit after tax grew about 8% to Rs. 262.33 million. Sequentially, both revenue and profit declined compared to Q4 FY25 (consolidated PAT of Rs. 344.44 million). The Board also approved the allotment of 375 equity shares of Rs. 2 each under the Rossari ESOP 2019 at an exercise price of Rs. 425 per share, taking total issued equity shares to 55,366,966. The results were subjected to a limited review by Walker Chandiok & Co LLP, with no qualifications flagged.
Strong topline growth year-on-year is a positive, but the slight dip in consolidated profit and sequential decline from Q4 FY25 suggest margin pressure that may concern investors. The ESOP allotment of just 375 shares is negligible and has no meaningful dilution effect.